Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Turnstone Biologics Corp. (TSBX)
NASDAQ:TSBX
RESEARCH TOOLSreports
Turnstone Biologics Corp. (TSBX) Stock Price & Analysis
21 Followers
TSBX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.63 - $13.20
Previous Close$2.66
Volume116.29K
Average Volume (3M)180.09K
Market Cap
$64.07M
Enterprise Value-$13.61M
Total Cash (Recent Filing)$77.85M
Total Debt (Recent Filing)$2.72M
Price to Earnings (P/E)-0.8
Beta6.60
Next Earnings
May 13, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding23,128,454
10 Day Avg. Volume134,656
30 Day Avg. Volume180,085
Standard Deviation0.40
R-Squared0.08
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)0.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.00T>
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Turnstone Biologics Corp. News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentSignificant investor interest is expected around the upcoming clinical update for Turnstone's TBio-4101, which could serve as a pivotal moment for the company's profile in the medical community.
Funding And Financial StabilityTurnstone Biologics secures non-dilutive funding, extending its financial runway and facilitating the continued advancement of its therapeutic pipeline.
Industry Trends And ComparablesTurnstone Biologics stands to gain momentum in the TIL field, as the recent FDA approval of a peer's therapy underscores the sector's potential and growing investor interest.
Bears Say
Clinical Trial UncertaintyThe success of Turnstone’s lead candidate TBio-4101 in human trials is still uncertain, pending upcoming clinical data.
Commercial ChallengesIovance is anticipated to face commercial challenges due to capacity constraints at authorized treatment centers and TIL-specific adoption complexities.
Operational ComplexitiesNotable complications such as the requirement for in-patient expertise and surgical tumor resection may limit the growth of treatment centers and infusions.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSBX FAQ
What was Turnstone Biologics Corp.’s price range in the past 12 months?
Turnstone Biologics Corp. lowest stock price was $1.63 and its highest was $13.20 in the past 12 months.
What is Turnstone Biologics Corp.’s market cap?
Currently, no data Available
When is Turnstone Biologics Corp.’s upcoming earnings report date?
Turnstone Biologics Corp.’s upcoming earnings report date is May 13, 2024 which is 7 days ago.
How were Turnstone Biologics Corp.’s earnings last quarter?
Turnstone Biologics Corp. released its earnings results on Mar 21, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.863 by $0.133.
Is Turnstone Biologics Corp. overvalued?
According to Wall Street analysts Turnstone Biologics Corp.’s price is currently Overvalued.
Does Turnstone Biologics Corp. pay dividends?
Turnstone Biologics Corp. does not currently pay dividends.
What is Turnstone Biologics Corp.’s EPS estimate?
Turnstone Biologics Corp.’s EPS estimate is -$0.78.
How many shares outstanding does Turnstone Biologics Corp. have?
Turnstone Biologics Corp. has 23,128,454 shares outstanding.
What happened to Turnstone Biologics Corp.’s price movement after its last earnings report?
Turnstone Biologics Corp. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.863. Following the earnings report the stock price went down -5.281%.
Which hedge fund is a major shareholder of Turnstone Biologics Corp.?
Currently, no hedge funds are holding shares in TSBX
---
Turnstone Biologics Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-98.71%
Trailing 12-Months
Asset Growth
2.31%
Trailing 12-Months
Company Description
Turnstone Biologics Corp.
Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The Company is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient¿s tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
---
TSBX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering TSBX
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-14.65%
assigned a buy rating 6 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -14.65% per trade.
---